Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges - PubMed

2 hours ago

Antibody-drug conjugates (ADCs) are rapidly growing anticancer therapies that target tumor cells with potent payloads while improving safety in both hematologic and solid tumors.
The review highlights the biology of ADCs and discusses future directions, including their expansion into earlier-stage treatments and combination therapies.
Key challenges emphasized include the need for careful patient selection and effective toxicity management as ADC use evolves.
One author discloses a conflict of interest as founder and CSO of an ADC development company, while another is an employee of Eli Lilly, and a third serves as an unpaid advisor to Beacon.

Hasty Briefsbeta